23 July 2022

MEMORANDUM FOR: KARINE JEAN-PIERRE
ASSISTANT TO THE PRESIDENT AND
WHITE HOUSE PRESS SECRETARY

FROM: KEVIN C. O’CONNOR, D.O., FAAFP
PHYSICIAN TO THE PRESIDENT

SUBJECT: President Biden SARS-CoV-2 Update

President Biden completed his second full day of PAXLOVID last night. His symptoms continue to improve. His primary symptoms, though less troublesome, now include sore throat, rhinorrhea, loose cough and body aches. His voice remains deep. His pulse, blood pressure, respiratory rate and temperature remain entirely normal. His oxygen saturation continues to be excellent on room air. His lungs remain clear.

The President continues to tolerate treatment well. We will continue PAXLOVID as planned. His symptoms will continue to be treated supportively with oral hydration, acetaminophen (TYLENOL), and the albuterol inhaler that he uses as needed for cough (2-3 times a day). He is experiencing no shortness of breath at all. He will continue low dose aspirin as an alternative type of blood thinner.

Our preliminary sequencing results have returned. The President’s causative agent is most likely the BA5 variant. This is the SARS-CoV-2 variant which is responsible for 75-80% of infections in the United States at this time. This data does not affect the treatment plan in any way.

The President is responding to therapy as expected. The BA5 variant is particularly transmissible and he will continue to isolate in accordance with Centers for Disease Control and Prevention (CDC) recommendations. We will continue to monitor him closely, during this very common outpatient treatment regimen.

As promised, I will keep your office updated with any changes in his condition or treatment plan.

Respectfully submitted,

Kevin C. O’Connor, D.O., FAAFP
Physician to the President
Associate Professor, The George Washington University School of Medicine & Health Sciences